These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 31171029)

  • 41. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
    Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
    Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime.
    Chanderraj R; Admon AJ; He Y; Nuppnau M; Albin OR; Prescott HC; Dickson RP; Sjoding MW
    JAMA Intern Med; 2024 Jul; 184(7):769-777. PubMed ID: 38739397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
    Forde C; McMullan R; Clarke M; Wilson RH; Plummer R; Grayson M; McDowell C; Agus A; Doran A; McAuley DF; Thomas AL; Barnes RA; Adams R; Chau I; Coyle V
    Trials; 2020 May; 21(1):431. PubMed ID: 32460818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs.
    Duszynska W; Taccone FS; Switala M; Hurkacz M; Kowalska-Krochmal B; Kübler A
    Int J Antimicrob Agents; 2012 Feb; 39(2):153-8. PubMed ID: 22154855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].
    Richter DC; Heininger A; Brenner T; Hochreiter M; Bernhard M; Briegel J; Dubler S; Grabein B; Hecker A; Krüger WA; Mayer K; Pletz MW; Störzinger D; Pinder N; Hoppe-Tichy T; Weiterer S; Zimmermann S; Brinkmann A; Weigand MA; Lichtenstern C
    Anaesthesist; 2017 Oct; 66(10):737-761. PubMed ID: 28980026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study protocol for ADAPT-TDM: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring.
    Pai Mangalore R; Chai MG; Pope J; Lee SJ; Padiglione A; Diehl A; Roberts L; Sim K; Rawson-Harris P; Wicha S; Schneider HG; Peel TN; Jenney A; Ayton D; Peleg AY; Udy AA
    BMJ Open; 2024 Jul; 14(6):e083635. PubMed ID: 38951004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study.
    Kühn D; Metz C; Seiler F; Wehrfritz H; Roth S; Alqudrah M; Becker A; Bracht H; Wagenpfeil S; Hoffmann M; Bals R; Hübner U; Geisel J; Lepper PM; Becker SL
    Crit Care; 2020 Nov; 24(1):664. PubMed ID: 33239110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin-Tazobactam in Obese Patients.
    Veillette JJ; Winans SA; Maskiewicz VK; Truong J; Jones RN; Forland SC
    Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):385-394. PubMed ID: 33743171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Empirical meropenem versus piperacillin/tazobactam for adult patients with sepsis (EMPRESS) trial: Protocol.
    Granholm A; Munch MW; Meier N; Sjövall F; Helleberg M; Hertz FB; Kaas-Hansen BS; Thorsen-Meyer HC; Andersen LW; Rasmussen BS; Andersen JS; Albertsen TL; Kjær MN; Jensen AKG; Lange T; Perner A; Møller MH
    Acta Anaesthesiol Scand; 2024 Sep; 68(8):1107-1119. PubMed ID: 38769040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
    Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
    Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock-a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial.
    David S; Bode C; Stahl K;
    Trials; 2023 Apr; 24(1):277. PubMed ID: 37061693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.
    D'Agostino C; Rhodes NJ; Skoglund E; Roberts JA; Scheetz MH
    J Infect Chemother; 2015 Oct; 21(10):742-6. PubMed ID: 26143049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae.
    Gould M; Ginn AN; Marriott D; Norris R; Sandaradura I
    Int J Antimicrob Agents; 2019 Aug; 54(2):240-244. PubMed ID: 31108222
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive performance of multi-model approaches for model-informed precision dosing of piperacillin in critically ill patients.
    Schatz LM; Greppmair S; Kunzelmann AK; Starp J; Brinkmann A; Roehr A; Frey O; Hagel S; Dorn C; Zoller M; Scharf C; Wicha SG; Liebchen U
    Int J Antimicrob Agents; 2024 Oct; 64(4):107305. PubMed ID: 39146997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.